The GLP-1 compounding picture changed after the shortages resolved. Compounded GLP-1 is no longer a simple “shortage workaround” — it needs a defensible, patient-specific structure.
Clinical governance reviewed by Armando A Falcon, MD (FL ME 84789) · Florida regulatory framework reviewed August 2026.
Compounded semaglutide and tirzepatide should not be treated as generic substitutes a clinic can routinely source and market. As of the August 2026 review, these products are not on FDA’s shortage list, and FDA has ended the shortage-based enforcement-discretion periods that previously allowed broad compounding. Verify the current status before building a business model around it.
For §503A compounding, federal law restricts regular or inordinate compounding of products that are essentially copies of commercially available drugs. FDA has indicated an individual-patient compounded product may fall outside the “essentially a copy” restriction when the prescriber determines and documents a change that produces a significant difference for that identified patient — assuming the other statutory conditions are met.
A model built on “everyone gets compounded GLP-1 because it’s cheaper” is not the same as “a prescriber identifies an individual patient need that supports a compounded preparation under the applicable framework.” That distinction is commercially and legally important.
FDA has reported concerns involving compounded semaglutide and tirzepatide — fraudulent labels, pharmacies named that did not make the product, improper shipping, dosing errors, and salt forms — and has stepped up enforcement against marketing compounded products as “generic,” “the same as,” or “clinically proven equivalent” to the approved drugs. Review your clinic’s marketing accordingly.
Compounded GLP-1 is no longer a simple shortage workaround. You need a defensible patient-specific prescribing, pharmacy, sourcing, product-verification, and marketing structure — and you should re-check current FDA status before any product decision.
Disclaimer — B2B clinical-governance & compliance education only. This content is general business, clinical-governance, and compliance information for healthcare practices. It does not create a physician-patient relationship, provide patient-specific medical advice or prescribing authority, or constitute legal advice. Requirements vary by ownership, services offered, provider credentials, payer model, facility type, and whether a practice is licensed or exempt — clinics remain responsible for independently verifying the current laws, rules, and professional requirements that apply to their structure and services before implementation.
FDA — concerns with unapproved GLP-1 drugs used for weight loss
FDA — compounding policies as national GLP-1 supply stabilizes
FDA — compounded drug products that are essentially copies under §503A
FDA — Drug Shortages database
Florida Statutes Chapter 465 — Pharmacy Act (compounding & dispensing)
Weight Loss & GLP-1 — medical director services
All Florida medical-director resources
Medical director services across selected Central, South, and Gulf Coast Florida markets — Miami & Fort Lauderdale, Palm Beach County, Orlando, Tampa Bay, Sarasota & Bradenton, Fort Myers & Naples. See areas we serve. Clinic acceptance and physician availability are confirmed for each location.
Under the medical direction of Armando A Falcon, MD (FL ME 84789). Serving approved Central, South, and Gulf Coast Florida markets; clinic acceptance and physician availability confirmed individually. Call or WhatsApp +1 (305) 877-7507.